PacBio Welcomes Dr. Michael Eberle as Vice President of Computational Biology
PacBio (NASDAQ: PACB) has appointed Michael Eberle, Ph.D., as Vice President of Computational Biology. Eberle, a seasoned genomics expert with over 20 years of experience, will lead the bioinformatics and data sciences program to enhance PacBio’s genomic analysis capabilities. His leadership, particularly from his previous role at Illumina, is expected to drive innovation and support the growing global customer base. The company remains committed to its mission of advancing genomic research through long- and short-read sequencing technologies.
- Appointing Michael Eberle adds 20 years of genomics experience to PacBio's leadership.
- Eberle's expertise aims to enhance bioinformatics and data sciences, likely improving customer offerings.
- The company is positioned to innovate and scale its genomic analysis capabilities.
- None.
Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program
MENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology. Michael will be responsible for leading the company’s bioinformatics and data sciences program to enhance PacBio’s genomic analysis offerings.
Michael is a genomics industry veteran with more than 20 years of experience. For the last 15 years, Michael has been a leader in the research and development organization at Illumina, most recently as a Vice President and Distinguished Scientist. Prior to that position, Michael was a research scientist at several leading academic institutions. Michael earned a Bachelor of Science in Physics from the University of Washington and a Master of Science and Ph.D. in Geophysics from Brown University.
“Michael joins us at a critical time for PacBio as we continue to drive innovation and scale our bioinformatics capabilities to meet the needs of a diverse and rapidly growing global customer base,” said Christian Henry, President and Chief Executive Officer at PacBio. “His experience leading teams at the intersection of scientific research and product development across both research and clinical markets will help PacBio grow critical competencies in computational biology, genome assembly and data science.”
“There has never been a more exciting time to work in genomics than today, the pace of discovery and its potential impact improving the human condition is unparalleled in our history,” said Michael Eberle, Ph.D., Vice President of Computational Biology at PacBio. “I am thrilled to work with PacBio’s native long-read sequencing technology to better understand genetic variability in the difficult parts of the genome for both clinical and research applications.”
PacBio is uniquely positioned in the market as a company with both long- and short-read sequencing technologies.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate sequencing platforms. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to future availability, uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with PacBio’s efforts regarding scaling and enhancing its genomic analysis offerings; growing critical competencies in computational biology, genome assembly and data science; and efforts to better understand genetic variability in certain parts of the genome; and other future events. Reported results should not be considered an indication of future performance. Forward-looking statements are subject to known and unknown risks, uncertainties, potential changes in circumstances, and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements in this press release. Factors that could materially affect actual results can be found, and readers are encouraged to read the full cautionary statements contained, in PacBio's filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q. These forward-looking statements are based on current expectations and speak only as of the date hereof. PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
FAQ
What is the recent appointment at PacBio?
What will Michael Eberle's role be at PacBio?
How many years of experience does Michael Eberle have in genomics?
What company did Michael Eberle work for before joining PacBio?
What technologies does PacBio specialize in?
